Vol. 3 No. 2 (2023)
Reimbursement Recommendations

Axicabtagene Ciloleucel (Yescarta)

Published February 22, 2023

Key Messages

  • CADTH recommends that Yescarta should be reimbursed by public drug plans for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, who are eligible for autologous stem cell transplant (ASCT) if certain conditions are met.
  • Yescarta should only be covered to treat adults with DLBCL or HGBL that did not respond to or relapsed within 12 months of first-line therapy and are eligible for ASCT.
  • Yescarta should only be reimbursed for patients who have not yet been treated with chimeric antigen receptor (CAR) T-cell therapy, are in relatively good health, and if the cost of Yescarta is reduced. It should be prescribed and administered by clinicians with expertise in lymphomas and CAR T-cell therapy in a hospital setting with adequate resources.